Key Publications

Lorenzo J, Barton B, Arnold SS, North KN (2015) Developmental trajectories of young children with neurofibromatosis type 1: a longitudinal study from 21 to 40 months of age. J Pediatr 166(4):1006-12

Payne JM, Pride NA & North KN (2014). Cognition and behaviour in neurofibromatosis type 1: pathogenesis and emerging therapies. In M Karajannis & J Allen (Eds) Neurofibromatosis Type 1: Symptoms, Treatment and Prognosis. Nova Science Publishers

Payne JM, Pickering T, Porter M, Oates EC, Walia N, Prelog K, North KN (2014) Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18 year study. Am J Med Genet A 164:661-5

Champion JA, Rose KJ, Payne JM, Burns J, North KN (2014) Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol

Pride NA, Korgaonkar MS, Barton B, Payne JM, North KN (2014) The genetic and neuroanatomical basis of social dysfunction – lessons from neurofibromatosis. Hum Brain Mapp 35(5): 2372-82

Payne JM, Barton B, Shores EA, North KN (2013) Visuospatial learning in children with NF1: from mouse behavioral phenotype to clinical trials. Journal of Neurology 260: 214-220

Payne JM (2013) Autism spectrum disorder symptomatology in children with neurofibromatosis type 1. Developmental Medicine and Child Neurology 55: 100-101

Oates EC, Payne JM, Foster SL, Clarke NF, North KN (2013) Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge. Am J Med Genet A. 161A(4):659-66